KM Research Hub

LITERATURE

原始候选快照

v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。

导出 CSV
论文标识日期入排置信度入排依据KM 状态
Two-year imaging outcomes from a phase 3 randomized trial of secukinumab in patients with non-radiographic axial spondyloarthritis.Arthritis Res TherPMID 37194094PMC101867672023-May-160.98未发现恶性肿瘤人群证据。待处理
Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial.LancetPMID 37116523无 PMCID2023-May-130.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.N Engl J MedPMID 37163621无 PMCID2023-May-110.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy.N Engl J MedPMID 37163622无 PMCID2023-May-110.98未发现恶性肿瘤人群证据。待处理
Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma.N Engl J MedPMID 37163623PMC102578982023-May-110.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non-Small-Cell Lung Cancer.J Clin OncolPMID 37146426无 PMCID2023-May-100.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
A phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial to verify the efficacy and safety of ansofaxine (LY03005) for major depressive disorder.Transl PsychiatryPMID 37164957PMC101711572023-May-100.98未发现恶性肿瘤人群证据。待处理
Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.Blood Cancer JPMID 37156782PMC101666822023-May-090.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Stereotactic Body radiotherapy and pedicLE screw fixatioN During one hospital visit for patients with symptomatic unstable spinal metastases: a randomized trial (BLEND RCT) using the Trials within Cohorts (TwiCs) design.TrialsPMID 37143158PMC101579662023-May-040.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study.Clin Infect DisPMID 36660819PMC101561232023-May-030.98未发现恶性肿瘤人群证据。待处理
Brodalumab, an anti-interleukin-17 receptor A monoclonal antibody, in axial spondyloarthritis: 68-week results from a phase 3 study.Rheumatology (Oxford)PMID 36130275PMC101522972023-May-020.98未发现恶性肿瘤人群证据。待处理
High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538.J Clin OncolPMID 36623230PMC101509222023-May-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Results of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation.J Clin OncolPMID 36706347无 PMCID2023-May-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Socioeconomic Barriers to Randomized Clinical Trial Retention in Patients Treated With Adjuvant Radiation for Early-Stage Breast Cancer.Int J Radiat Oncol Biol PhysPMID 36724858无 PMCID2023-May-010.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Efficacy and Safety of Gadopiclenol for Contrast-Enhanced MRI of the Central Nervous System: The PICTURE Randomized Clinical Trial.Invest RadiolPMID 36729404PMC100903112023-May-010.95The trial is a randomized, phase III study of a contrast agent (gadopiclenol) for MRI, not a therapeutic oncology trial. It evaluates diagnostic imaging efficacy and safety, not time-to-event clinical outcomes like survival or progression.待处理
Phase III Randomized Non-Inferiority Study of OSS Versus PEG + Electrolyte Colonoscopy Preparation in Adolescents.J Pediatr Gastroenterol NutrPMID 36821851PMC100974892023-May-010.98未发现恶性肿瘤人群证据。待处理
Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis.Clin J Am Soc NephrolPMID 36927680PMC102787892023-May-010.98未发现恶性肿瘤人群证据。待处理
Final analysis of a randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311).Int J Gynecol CancerPMID 36997229无 PMCID2023-May-010.96明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。待处理
Levonorgestrel 52-mg Intrauterine Device Efficacy and Safety After More Than 8 Years of Use.Obstet GynecolPMID 37023451无 PMCID2023-May-010.98未发现恶性肿瘤人群证据。待处理
The comparison of efficacy and safety evaluation of vacuum-assisted Elite 10-G system and the traditional BARD 14-G core needle in breast diagnosis: an open-label, parallel, randomized controlled trial.Int J SurgPMID 37042316PMC103893322023-May-010.95This is a Phase 3 randomized trial in oncology (breast cancer diagnosis), but it compares two diagnostic biopsy procedures (vacuum-assisted vs. core needle) and does not involve a drug intervention. The primary efficacy endpoint is diagnostic accuracy (a proportion), not a time-to-event endpoint such as OS, PFS, or DFS. Therefore, it does not meet the criteria for a drug-containing oncology trial with a time-to-event efficacy endpoint.待处理
Efficacy of Olanzapine in Addition to Standard Triplet Antiemetic Therapy for Cisplatin-Based Chemotherapy: A Secondary Analysis of the J-FORCE Randomized Clinical Trial.JAMA Netw OpenPMID 37129897PMC101550682023-May-010.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
Efficacy and Safety of a Protein-Based SARS-CoV-2 Vaccine: A Randomized Clinical Trial.JAMA Netw OpenPMID 37133864PMC101574292023-May-010.98未发现恶性肿瘤人群证据。待处理
Topical Esmolol Hydrochloride as a Novel Treatment Modality for Diabetic Foot Ulcers: A Phase 3 Randomized Clinical Trial.JAMA Netw OpenPMID 37184839PMC125207082023-May-010.98未发现恶性肿瘤人群证据。待处理
Incidence of Primary End Point Changes Among Active Cancer Phase 3 Randomized Clinical Trials.JAMA Netw OpenPMID 37195664PMC101931802023-May-010.80This is a cross-sectional methodological study analyzing changes in primary endpoints among phase 3 oncology RCTs. It is not a report of an original trial result with a drug intervention and a time-to-event efficacy endpoint. The study itself is observational and methodological, not an eligible trial report.待处理
Testing a Novel Deliberate Practice Intervention to Improve Diagnostic Reasoning in Trauma Triage: A Pilot Randomized Clinical Trial.JAMA Netw OpenPMID 37195666PMC101931862023-May-010.98未发现恶性肿瘤人群证据。待处理
Effectiveness of S-1-Based Chemoradiotherapy in Patients 70 Years and Older With Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.JAMA Netw OpenPMID 37195667PMC101931852023-May-010.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
A co-formulation of pramlintide and insulin A21G (ADO09) improves postprandial glucose and short-term control of mean glucose, time in range, and body weight versus insulin aspart in adults with type 1 diabetes.Diabetes Obes MetabPMID 36633505无 PMCID2023-May0.98未发现恶性肿瘤人群证据。待处理
Dupilumab efficacy and safety in Latin American patients with uncontrolled, moderate-to-severe asthma: phase 3 LIBERTY ASTHMA QUEST study.J AsthmaPMID 36066123无 PMCID2023-May0.98未发现恶性肿瘤人群证据。待处理
Favipiravir in patients hospitalised with COVID-19 (PIONEER trial): a multicentre, open-label, phase 3, randomised controlled trial of early intervention versus standard care.Lancet Respir MedPMID 36528039PMC98917372023-May0.98未发现恶性肿瘤人群证据。待处理
Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial.Am J Kidney DisPMID 36535535无 PMCID2023-May0.98未发现恶性肿瘤人群证据。待处理
Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studies.J Am Acad DermatolPMID 36574595无 PMCID2023-May0.98未发现恶性肿瘤人群证据。待处理
NOV03 for Dry Eye Disease Associated with Meibomian Gland Dysfunction: Results of the Randomized Phase 3 GOBI Study.OphthalmologyPMID 36574848无 PMCID2023-May0.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of janagliflozin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled on diet and exercise: A multicentre, randomized, double-blind, placebo-controlled, Phase 3 trial.Diabetes Obes MetabPMID 36594724无 PMCID2023-May0.98未发现恶性肿瘤人群证据。待处理
Itacitinib Population Pharmacokinetics and Exposure-Response in Patients With Acute Graft-Versus-Host Disease.J Clin PharmacolPMID 36601737无 PMCID2023-May0.98未发现恶性肿瘤人群证据。待处理
Immunogenicity and safety of a 10-valent pneumococcal conjugate vaccine administered as a 2 + 1 schedule to healthy infants in The Gambia: a single-centre, double-blind, active-controlled, randomised, phase 3 trial.Lancet Infect DisPMID 36638819无 PMCID2023-May0.98未发现恶性肿瘤人群证据。待处理
Camrelizumab Plus Carboplatin and Pemetrexed as First-Line Treatment for Advanced Nonsquamous NSCLC: Extended Follow-Up of CameL Phase 3 Trial.J Thorac OncolPMID 36646210无 PMCID2023-May0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Safety, immunogenicity, and lot-to-lot consistency of a multidose Sabin strain-based inactivated polio vaccine: a phase III, randomized, blinded, positive-control clinical trial in infants aged 2 months.Int J Infect DisPMID 36682682无 PMCID2023-May0.98未发现恶性肿瘤人群证据。待处理
Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study.Lancet Respir MedPMID 36702146无 PMCID2023-May0.98未发现恶性肿瘤人群证据。待处理
Safety of upadacitinib in Latin American patients with rheumatoid arthritis: an integrated safety analysis of the SELECT phase 3 clinical program.Clin RheumatolPMID 36715850PMC98862072023-May0.96主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。待处理
Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA).J NeurolPMID 36735057PMC98976182023-May0.98未发现恶性肿瘤人群证据。待处理
Changes in migraine interictal burden following treatment with galcanezumab: Results from a phase III randomized, placebo-controlled study.HeadachePMID 36797223无 PMCID2023-May0.98未发现恶性肿瘤人群证据。待处理
Factors influencing the presence of potentially explosive gases during colonoscopy: Results of the SATISFACTION study.Clin Transl SciPMID 36799346PMC101760102023-May0.98未发现恶性肿瘤人群证据。待处理
Effect of food on the pharmacokinetics of zoliflodacin granules for oral suspension: Phase I open-label randomized cross-over study in healthy subjects.Clin Transl SciPMID 36824016PMC101760082023-May0.98未发现恶性肿瘤人群证据。待处理
Efficacy and safety of AP-Bio®(KalmCold®) in participants with uncomplicated upper respiratory tract viral infection (common cold) - A phase III, double-blind, parallel group, randomized placebo-controlled trial.Complement Ther MedPMID 36842634无 PMCID2023-May0.98未发现恶性肿瘤人群证据。待处理
Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2).Am J Clin DermatolPMID 36855020PMC99743842023-May0.98未发现恶性肿瘤人群证据。待处理
Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer.Ann OncolPMID 36858151无 PMCID2023-May0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理
CANNA-TICS: Efficacy and safety of oral treatment with nabiximols in adults with chronic tic disorders - Results of a prospective, multicenter, randomized, double-blind, placebo controlled, phase IIIb superiority study.Psychiatry ResPMID 36878177无 PMCID2023-May0.98未发现恶性肿瘤人群证据。待处理
Six-Year Survival Outcomes for Patients with HER2-Positive Early Breast Cancer Treated with CT-P6 or Reference Trastuzumab: Observational Follow-Up Study of a Phase 3 Randomised Controlled Trial.BioDrugsPMID 36881323PMC101957252023-May0.98原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。待处理
Efficacy and safety of the selective TYK2 inhibitor, deucravacitinib, in Japanese patients with moderate to severe plaque psoriasis: Subgroup analysis of a randomized, double-blind, placebo-controlled, global phase 3 trial.J DermatolPMID 36882942无 PMCID2023-May0.98未发现恶性肿瘤人群证据。待处理
OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.Eur J CancerPMID 36893711PMC105852402023-May0.96属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。待处理